Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts
Source: SeekingAlpha
2025-12-19 12:04:39 ET
...
Read the full article on Seeking Alpha
For further details see:
Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts
Kalaris Therapeutics Inc.
NASDAQ: KLRS
KLRS Trading
-8.92% G/L:
$9.09 Last:
37,960 Volume:
$9.50 Open:
KLRS Latest News
January 28, 2026 04:05:00 pm
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
December 17, 2025 05:59:02 pm
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
December 17, 2025 04:01:00 pm
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD
November 12, 2025 08:00:00 am
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates
KLRS Stock Data
$187,398,228
4,677,475
1.26%
26
N/A
Biotechnology & Life Sciences
Healthcare
US
Berkeley Heights
